In 2015, the ASPIRATION, a phase II, single‐arm study was conducted to study the efficacy of first‐line erlotinib therapy and post‐progression erlotinib therapy in patients with stage IV and EGFR mutation‐positive NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.